



January 19, 2024

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. (“Teva”) submits this information pursuant to 18 V.S.A. § 4637(b). Today, January 19, 2024, Teva released the following generic prescription drug to the commercial market:

NDC	Product Description	WAC
00591-4390-96	MIFEPRISTONE TABLETS 300MG 28	\$16,733.61

Teva provides this notice consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this notice, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Thank you for your consideration.

Sincerely,

A handwritten signature in cursive script that reads "Jacqueline O'Connell".

Jacqueline O'Connell
Director Commercial Compliance

Teva Pharmaceuticals USA, Inc.
Morris Corporate Center III, Building B | 400 Interpace Parkway | Parsippany, NJ 07054
Tel. 973.658.0321 | Jacqueline.O'Connell@tevapharm.com | www.tevausa.com